Tailor-Made vaccine aims to stop cancer return in High-Risk patients
NCT ID NCT07504484
First seen Apr 04, 2026 · Last updated Jun 22, 2026 · Updated 15 times
Summary
This early-phase study tested a personalized immunotherapy (iNeo-Vac-P01) in 6 patients with stage III colorectal or non-small cell lung cancer who had already completed surgery and standard adjuvant therapy. The vaccine was designed to target unique neoantigens from each patient's tumor, aiming to activate the immune system to eliminate any remaining cancer cells and prevent recurrence. The main goals were to check safety and see if the approach could improve recurrence-free survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, Zhejiang, 310009, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized neoantigen peptides plus GM-CSF
What this could lead to
If it works, this could lead to a personalized vaccine that helps prevent cancer from coming back after surgery and standard therapy.
What could go wrong
This was a very small, early-phase trial with only 6 participants, so results may not apply to everyone. The treatment is complex and tailored to each person, making it hard to scale.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.